Full Year 2024 Results Key Financial Results Net loss: US$70.5m (loss widened ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination ...

As of December 31, 2024, cash and cash equivalents were $111.0 million, compared to $134.3 million as of December 31, 2023. The Company also ...

Werewolf Therapeutics (HOWL) provided a business update and outlined its strategic outlook and expected milestones for 2025. “2024 was a year of execution for Werewolf in which we reported data ...

In 2024 it announced it was working on an animated ... Here's what to know about "Taylor Lautner: Werewolf Hunter," and how it ties to "Twilight." The supernatural show will give an insight ...

“Werewolf made considerable progress in 2024 with promising preliminary evidence of durable anti-tumor activity and tolerability for cytokine therapeutics as we completed the dose-escalation ...

- Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first ...